Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction.
The neonatal Fc receptor, FcRn, prolongs the half-life of IgG in the serum and represents a potential therapeutic target for the treatment of autoimmune disease. Small molecules that block the protein-protein interactions of human IgG-human FcRn may lower pathogenic autoantibodies and provide effective treatment. A novel class of quinoxalines has been discovered as antagonists of the IgG:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12
CHEMICAL GENE-N GENE-Y GENE-Y GENE-N GENE-Y GENE-Y GENE-N GENE-Y GENE-N GENE-Y GENE-N
quinoxalines human IgG human FcRn FcRn IgG FcRn neonatal Fc receptor IgG human neonatal Fc receptor hIgG hFcRn human immunoglobulin G